NovaBay Pharmaceuticals Inc (NBY) - Total Liabilities
Based on the latest financial reports, NovaBay Pharmaceuticals Inc (NBY) has total liabilities worth $31.86 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NBY cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
NovaBay Pharmaceuticals Inc - Total Liabilities Trend (2003–2025)
This chart illustrates how NovaBay Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of NovaBay Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yuhwa Securities Co Ltd
KO:003465
|
Korea | ₩217.69 Billion |
|
Modi Rubber Limited
NSE:MODIRUBBER
|
India | Rs938.57 Million |
|
FiEE, Inc.
NASDAQ:FIEE
|
USA | $3.86 Million |
|
Pelat Timah Nusantara Tbk
JK:NIKL
|
Indonesia | Rp57.12 Million |
|
Raval ACS Ltd
TA:RVL
|
Israel | ILA110.61 Million |
|
American West Metals Ltd
AU:AW1
|
Australia | AU$13.81 Million |
|
Vitreous Glass Inc
V:VCI
|
Canada | CA$1.50 Million |
|
Mishorim Real Estate Investments
TA:MSHR
|
Israel | ILA1.90 Billion |
Liability Composition Analysis (2003–2025)
This chart breaks down NovaBay Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See NovaBay Pharmaceuticals Inc (NBY) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NovaBay Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NovaBay Pharmaceuticals Inc (2003–2025)
The table below shows the annual total liabilities of NovaBay Pharmaceuticals Inc from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $31.86 Million | +796.99% |
| 2024-12-31 | $3.55 Million | -37.90% |
| 2023-12-31 | $5.72 Million | -2.14% |
| 2022-12-31 | $5.84 Million | -57.67% |
| 2021-12-31 | $13.81 Million | +372.84% |
| 2020-12-31 | $2.92 Million | -71.50% |
| 2019-12-31 | $10.25 Million | +132.52% |
| 2018-12-31 | $4.41 Million | -41.12% |
| 2017-12-31 | $7.49 Million | -9.60% |
| 2016-12-31 | $8.28 Million | -18.62% |
| 2015-12-31 | $10.18 Million | +78.85% |
| 2014-12-31 | $5.69 Million | -20.26% |
| 2013-12-31 | $7.13 Million | +37.56% |
| 2012-12-31 | $5.19 Million | -21.65% |
| 2011-12-31 | $6.62 Million | +31.70% |
| 2010-12-31 | $5.03 Million | +20.30% |
| 2009-12-31 | $4.18 Million | -36.93% |
| 2008-12-31 | $6.62 Million | -31.01% |
| 2007-12-31 | $9.60 Million | -4.49% |
| 2006-12-31 | $10.05 Million | +3142.90% |
| 2005-12-31 | $310.00K | -39.57% |
| 2003-12-31 | $513.00K | -- |
About NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc. engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol. Its services intend to support protocol-level services, including staking, governance participation, validation, and related activities. T… Read more